Skip to main content

By UKidney Staff. Posted in General Nephrology.

Interactive case-based learning in ADPKD

  • SV Splash Small

    LEARNING OBJECTIVES

    At the end of this program, participants will be able to:

    • Evaluate risk progression in ADPKD
    • Identify patients at high risk of progression
    • Determine whether patients are suitable candidates for tolvaptan treatment

    SECTION 3 CREDITS:

    Speaking Volumes 3: Portraits of PKD has been approved by the Canadian Society of Nephrology and is an accredited Self-Assessment Program (Section 3), as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada. Devised to achieve scientific integrity, objectivity and balance, this program was made possible through an unrestricted educational grant from Otsuka Canada Pharmaceutical Inc. (OCPI).

    To claim two (2) credits per hour of educational activity, you must complete the Self-Assessment Test, save your results and the Certificate of Completion, and enter this activity into MAINPORT (http://www.mainport.org).

    DISCLAIMER

    This educational program was developed and reviewed by a panel of ten (10) Canadian nephrologists with experience in diagnosing and managing autosomal dominant polycystic kidney disease (ADPKD), and who have used ADPKD-specific medication in clinical trials and in real life.

    There were no evidence-based clinical practice guidelines for the diagnosis and management of ADPKD at the time this program was developed. The opinions expressed in this program are those of the program faculty at the time the program was developed, and are not to be considered as directive.

    CONTENT DEVELOPMENT COMMITTEE

    Philip McFarlane, MD, PhD, FRCP(C) - Chair
    Clinical Investigator, Division of Nephrology, St. Michael's Hospital
    Assistant Professor, University of Toronto
    Toronto, Ontario
    Ahsan Alam, MDCM, MS, FRCP(C)
    Nephrologist, MUHC McGill, Glen Site
    Associate Professor of Medicine, McGill University
    Montreal, Quebec
    Daniel Bichet, MD
    Nephrologist, Sacré-Cœur de Montréal Hospital
    Professor of Medicine and Molecular & Integrative Physiology, University of Montreal
    Montreal, Quebec
    Louis Girard, MD, MBT, FRCP(C)
    Nephrologist, Division of Nephrology, University of Calgary
    Clinical Assistant Professor, University of Calgary
    Calgary, Alberta
    York Pei, MD, FRCP(C)
    Nephrologist, Toronto General Hospital, University Health Network
    Professor of Medicine, University of Toronto
    Toronto, Ontario
    Paul René de Cotret, MD, FRCP(C), ABIM - Reviewer
    Director, Division of Nephrology, Laval University
    Professor of Medicine, Laval University
    Quebec City, Quebec
    Steven D. Soroka, BMus, MD, MSc, FRCP(C), EXTRA Fellow, CHE
    Nephrologist, Department of Medicine, Nova Scotia Health Authority
    Medical Lead, Central Zone Renal Program, Nova Scotia Health Authority
    Medical Lead, Pharmacy and Renal Program, Nova Scotia Health Authority
    Professor of Medicine, Dalhousie University
    Halifax, Nova Scotia
    Dr. Paul Tam, MD, FRCP(C), FACP
    Nephrologist, The Scarborough Hospital
    Medical Director, Scarborough Regional Nephrology Program
    Scarborough, Ontario
    Sheldon Tobe, MD, MScCH (HPTE), FRCP(C), FACP, FASH
    Nephrologist and Hypertension Specialist, Sunnybrook Health Sciences Centre
    HSF/NOSM Chair in Aboriginal and Rural Health Research
    Professor of Medicine, University of Toronto Toronto, Ontario
    Jordan Weinstein, MD, FRCP(C)
    Nephrologist, St. Michael's Hospital
    Assistant Professor of Medicine, University of Toronto
    Toronto, Ontario

  • CASE 1: David, a 31-year-old man with abnormal findings on abdominal ultrasound

    Begin
    Philip McFarlane, MD, PhD, FRCP(C) - Chair
    Clinical Investigator, Division of Nephrology, St. Michael's Hospital
    Assistant Professor, University of Toronto
    Toronto, Ontario

    Dr. Philip McFarlane is a clinical investigator in the Division of Nephrology and Chief Nephrologist in the Live Kidney Donor Program at St. Michael's Hospital in Toronto, as well as an Assistant Professor at the University of Toronto. He is a member of the Canadian Diabetes Association Clinical Practice Guidelines group, the Canadian Society of Nephrology guideline group and the Canadian Hypertension Education Program. 

    Dr. McFarlane completed his PhD in Health Economics at the institute for Medical Sciences at the University of Toronto, and his research interests include health economics and outcomes. He has published over 60 peer-­reviewed manuscripts and three book chapters.

  • CASE 2: Mark, a 35-year-old man with severe hypertension

    Ahsan Alam, MDCM, MS, FRCP(C)
    Nephrologist, MUHC McGill, Glen Site
    Associate Professor of Medicine, McGill University
    Montreal, Quebec

    Dr. Ahsan Alam is an Associate Professor of Medicine and Director of the Internal Medicine Residency Training Program at McGill University. He is also a staff nephrologist and member of the multi-organ transplant program at the Royal Victoria Hospital in Montreal.

    Dr. Alam completed a master’s degree in clinical research at the Sackler School of Graduate Biomedical Sciences at Tufts University in Boston. He has participated in several ADPKD clinical trials, including the TEMPO 3/4 Study. He was a member of the KDIGO Controversies Conference on ADPKD and speaks at the American Society of Nephrology pre-course on ADPKD.

  • CASE 3: Jillian, a 20-year-old woman being assessed as a transplant donor for her aunt with ADPKD

    Louis Girard, MD, MBT, FRCP(C)
    Nephrologist, Division of Nephrology, University of Calgary
    Clinical Assistant Professor, University of Calgary
    Calgary, Alberta

    Dr. Louis Girard joined the Division of Nephrology of the University of Calgary in July 2010 as a nephrologist and Clinical Assistant Professor. Within the Division of Nephrology, Dr. Girard focuses on clinical immunology and infectious diseases in chronic kidney disease patients. He is the Medical Director of the Glomerulonephritis Clinic and the Medical Co-Director of Apheresis. Furthermore, he has developed a multi-disciplinary Tuberous Sclerosis clinic that operates out of the Southern Alberta Renal Program, and is currently developing a multi-disciplinary clinic for patients with ADPKD.

    Dr. Girard has a strong clinical research interest. He is currently the local primary investigator on numerous global trials in glomerulonephritis and vasculitis. From an ADPKD perspective, he is a site primary investigator for the C-MAJOR registry and is currently a member of the Canadian Consensus Recommendation Committee.

    Dr. Girard has a strong commitment to education and has won numerous awards for his teaching contributions at all levels of medical training.

ukidneyisup